It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Treatment of locally advanced, unresectable head and neck squamous cell carcinoma (HNSCC) often yields only modest results with radiochemotherapy (RCT) as standard of care. Prognostic features related to outcome upon RCT might be highly valuable to improve treatment. Monocarboxylate transporters-1 and -4 (MCT1/MCT4) were evaluated as potential biomarkers. A cohort of HNSCC patients without signs for distant metastases was assessed eliciting 82 individuals eligible whereof 90% were diagnosed with locally advanced stage IV. Tumor specimens were stained for MCT1 and MCT4 in the cell membrane by immunohistochemistry. Obtained data were evaluated with respect to overall (OS) and progression-free survival (PFS). Protein expression of MCT1 and MCT4 in cell membrane was detected in 16% and 85% of the tumors, respectively. Expression of both transporters was not statistically different according to the human papilloma virus (HPV) status. Positive staining for MCT1 (n = 13, negative in n = 69) strongly worsened PFS with a hazard ratio (HR) of 3.1 (95%-confidence interval 1.6–5.7, p < 0.001). OS was likewise affected with a HR of 3.8 (2.0–7.3, p < 0.001). Multivariable Cox regression confirmed these findings. We propose MCT1 as a promising biomarker in HNSCC treated by primary RCT.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University Medical Center Göttingen, Clinic of Radiotherapy and Radiation Oncology, Göttingen, Germany (GRID:grid.411984.1) (ISNI:0000 0001 0482 5331)
2 University Medical Center Göttingen, Institute of Pathology, Göttingen, Germany (GRID:grid.411984.1) (ISNI:0000 0001 0482 5331)
3 University Medical Center Göttingen, Clinic of Otorhinolaryngology, Göttingen, Germany (GRID:grid.411984.1) (ISNI:0000 0001 0482 5331)
4 Radiology Munich, Department of Radiology, Nuclear Medicine and Radiotherapy, Munich, Germany (GRID:grid.411984.1); University of Regensburg, Department of Radiation Oncology, Medical Center, Regensburg, Germany (GRID:grid.7727.5) (ISNI:0000 0001 2190 5763)
5 Ludwig-Maximilians-University Munich, Department of Otorhinolaryngology, Head and Neck Surgery, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)